Can Wellbutrin Cause Increased Heart Rate?
Yes, bupropion (Wellbutrin) can cause tachycardia and elevated heart rate, though this effect is generally mild and occurs less frequently than with some other cardiovascular complications. The FDA drug label documents tachycardia as a recognized adverse effect, and clinical guidelines recommend monitoring blood pressure and heart rate, particularly during the first 12 weeks of treatment 1, 2, 3, 4.
Cardiovascular Effects Profile
Heart Rate and Blood Pressure Changes
Bupropion commonly causes increases in blood pressure but has minimal effect on resting heart rate in most patients 4, 5. The FDA label lists tachycardia among documented adverse reactions, though it occurs at relatively low frequency 4.
In patients with preexisting cardiovascular disease, bupropion caused a rise in supine blood pressure but had no significant effect on pulse rate in a study of 36 depressed patients with heart disease 5. This suggests blood pressure elevation is more consistent than heart rate changes.
When combined with naltrexone (naltrexone-bupropion ER), cardiovascular monitoring becomes more critical, as this combination specifically requires periodic blood pressure and heart rate monitoring, especially during the first 12 weeks 1, 2, 3.
Clinical Context and Risk Stratification
Patients with uncontrolled hypertension should not receive bupropion, particularly in combination formulations, as the medication can elevate both blood pressure and heart rate 2, 3.
Cardiovascular effects are dose-dependent and more pronounced in overdose situations. In toxic exposures, bupropion can cause significant cardiotoxicity including QRS widening, QTc prolongation, and ventricular dysrhythmias 6, 7.
The 2024 American Heart Association guidelines note that psychostimulants like methylphenidate carry monitoring requirements for tachycardia and hypertension, but bupropion is not specifically flagged with the same level of cardiovascular concern as tricyclic antidepressants or SNRIs at high doses 1.
Monitoring Recommendations
Essential Monitoring Parameters
Check baseline blood pressure and heart rate before initiating bupropion 2, 3.
Monitor blood pressure and heart rate periodically during treatment, with increased vigilance during the first 12 weeks 1, 2, 3. This is particularly important for patients on naltrexone-bupropion combinations.
Patients with cardiovascular disease require closer monitoring, though bupropion has a favorable cardiovascular profile compared to tricyclic antidepressants 5, 8.
When to Exercise Caution
Avoid bupropion in patients with uncontrolled hypertension 2, 3.
Use caution in patients with preexisting cardiovascular disease, though studies show bupropion is generally well-tolerated in this population with appropriate monitoring 5.
Consider alternative antidepressants if significant tachycardia or hypertension develops during treatment. In one study, 14% of patients with preexisting heart disease discontinued bupropion due to adverse effects, including exacerbation of baseline hypertension in two patients 5.
Comparative Safety Profile
Bupropion causes fewer cardiovascular side effects than tricyclic antidepressants, with minimal orthostatic hypotension, no significant conduction complications, and low rates of clinically significant heart rate changes 5, 9, 8.
Unlike tricyclic antidepressants, bupropion does not cause significant conduction delay or orthostatic hypotension 5, 9, 8.
The 2008 American College of Physicians guidelines note that while evidence on cardiovascular risks with second-generation antidepressants is scarce, weak evidence suggests venlafaxine (an SNRI) may be associated with increased cardiovascular events, but similar concerns are not highlighted for bupropion 1.
Clinical Pearls
Tachycardia from bupropion is typically mild and transient when it occurs at therapeutic doses 4, 5.
Administer the second dose of bupropion SR before 3 PM to minimize insomnia risk, which could indirectly affect heart rate through anxiety or sleep disturbance 2.
In overdose situations, cardiovascular toxicity becomes a major concern, with QRS widening and ventricular dysrhythmias possible 6, 7. Age, seizures, and ECG changes (QRS widening, QTc prolongation) are associated with adverse cardiovascular events in toxic exposures 7.
Patients with anxiety disorders may experience increased heart rate from anxiety exacerbation rather than direct drug effect, though bupropion efficacy is not significantly affected by comorbid anxiety 2.